◆英語タイトル:Vectura Group Plc (VEC) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8011976
◆発行会社(調査会社):
GlobalData
◆発行日:2017年12月14日
◆ページ数:53
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:医療機器
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Vectura Group Plc (Vectura) is a formulation and device business for inhaled airways products providing an integrated inhaled drug delivery platform. It develops inhalation products, to help patients suffering from airways diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, pulmonary fibrosis and other diseases. The company develops products based on a wide range of proprietary lung delivery technologies, including device and formulation capabilities. Vectura has a varied portfolio of drugs in clinical development, comprising several novel and generic programs that are partnered with several global biotechnology and pharmaceutical companies. Vectura is headquartered in Chippenham, Wiltshire, the UK.
Vectura Group Plc (VEC) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Vectura Group Plc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Vectura Group Plc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Vectura Group Plc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Vectura Group Plc, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
Vectura Group Plc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Vectura Group Plc, Medical Equipment, Deal Details 11
Asset Purchase 11
SkyePharma Acquires Novel Inhaled Therapy Platform from Pulmagen Therapeutics 11
Venture Financing 12
Activaero Secures US$6.8 Million In Series A Financing Round 12
Partnerships 14
Vectura Enters into Agreement with Dynavax Technologies 14
Vectura Enters into Co-Development Agreement with Propeller Health 15
Activaero Enters Into Distribution Agreement With Vivisol For Akita Jet Inhalation System 16
Activaero Enters Into Co-Development Agreement With TransMIT 17
Vectura, Tianjin KingYork Group And Zendex Bio Strategy Form Respiratory Joint Venture In China 18
Activaero Enters Into Collaboration With Forest Healthcare 20
Merger 21
SkyePharma Merges with Vectura 21
Equity Offering 23
SkyePharma Completes Private Placement Of Shares For US$187 Million 23
SkyePharma Completes Rights Offering Of Shares 24
Vectura Group Completes Private Placement Of Shares For US$46 Million 25
Acquisition 26
Vectura Acquires Activaero, Medical Device Company, For US$181 Million 26
Vectura Group Plc – Key Competitors 28
Vectura Group Plc – Key Employees 29
Vectura Group Plc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Joint Venture 30
Recent Developments 32
Financial Announcements 32
Sep 06, 2017: Vectura Group: 2017 Interim Results 32
Mar 21, 2017: Vectura Group: Preliminary Results for the nine-month period ended 31 December 2016 34
Mar 21, 2017: Vectura Group Announces Preliminary Results for the nine-month period ended 31 December 2016 36
May 26, 2016: Vectura Group – Preliminary Results for twelve months ending 31 March 2016 38
Corporate Communications 45
Nov 29, 2017: Vectura Group appoints Juliet Thompson to its Board of Directors 45
Mar 06, 2017: Vectura Group: Board Change 46
Jul 08, 2016: Dr John Brown, Non-Executive Director, confirms date to step down 47
Jul 05, 2016: Vectura Group Announces Board Committee changes post completion of merger with Skyepharma 48
Jun 10, 2016: Vectura Group announces Directorate Changes 49
Other Significant Developments 50
Feb 16, 2017: Vectura achieves £9 million royalty cap from GSK Ellipta® products 50
Jan 25, 2017: Seebri / Ultibro Breezhaler 2016 sales reach $512 million triggering $5 million milestone receipt 51
Jan 11, 2017: Vectura Group: Pre-close update 52
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53
List of Tables
Vectura Group Plc, Medical Equipment, Key Facts, 2016 2
Vectura Group Plc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Vectura Group Plc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Vectura Group Plc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Vectura Group Plc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Vectura Group Plc, Deals By Market, 2011 to YTD 2017 9
Vectura Group Plc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
SkyePharma Acquires Novel Inhaled Therapy Platform from Pulmagen Therapeutics 11
Activaero Secures US$6.8 Million In Series A Financing Round 12
Vectura Enters into Agreement with Dynavax Technologies 14
Vectura Enters into Co-Development Agreement with Propeller Health 15
Activaero Enters Into Distribution Agreement With Vivisol For Akita Jet Inhalation System 16
Activaero Enters Into Co-Development Agreement With TransMIT 17
Vectura, Tianjin KingYork Group And Zendex Bio Strategy Form Respiratory Joint Venture In China 18
Activaero Enters Into Collaboration With Forest Healthcare 20
SkyePharma Merges with Vectura 21
SkyePharma Completes Private Placement Of Shares For US$187 Million 23
SkyePharma Completes Rights Offering Of Shares 24
Vectura Group Completes Private Placement Of Shares For US$46 Million 25
Vectura Acquires Activaero, Medical Device Company, For US$181 Million 26
Vectura Group Plc, Key Competitors 28
Vectura Group Plc, Key Employees 29
Vectura Group Plc, Subsidiaries 30
Vectura Group Plc, Joint Venture 30